How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about lecanemab

Marketing authorisation indication

2.1

Lecanemab (Leqembi, Eisai) is indicated 'for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein Eε 4 (ApoE ε4) heterozygotes or non-carriers'.

Dosage in the marketing authorisation

Price

2.3

The list price of lecanemab is £275 for 200 mg solution for infusion and £545 for 500 mg solution or infusion (excluding VAT; company submission).

2.4

The company has a commercial arrangement, which would have applied if the lecanemab had been recommended.

Sustainability

2.5

For information, the Carbon Reduction Plan for UK carbon emissions is published at Eisai: Sustainability (webpage).